Systematic review of cancer presentations with a median survival of six months or less

Journal of Palliative Medicine

Volumn 15, Issue 2, 2012, Pages 175-185

  Salpeter, Shelley R ^a,b   Malter, Dawn S ^c   Luo, Esther J ^d   Lin, Albert Y ^b,e   Stuart, Brad ^a  

^a Sutter Care at Home   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Samaritan House Clinic   (United States)

^d KAISER PERMANENTE   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CETUXIMAB; ESTRAMUSTINE; IMATINIB; LAPATINIB; MELPHALAN; RITUXIMAB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AGE; BILIARY TRACT CANCER; BLADDER CARCINOMA; BRAIN CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; EASTERN COOPERATIVE ONCOLOGY GROUP SCALE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE GENITAL TRACT CANCER; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HEPATOBILIARY SYSTEM CANCER; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE GENITAL TRACT CANCER; MELANOMA; METASTASIS; MULTIPLE MYELOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK FACTOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; TERMINAL DISEASE; THERAPY EFFECT; THYROID CANCER; THYROID CARCINOMA; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

HUMANS; KARNOFSKY PERFORMANCE STATUS; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84857491316     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0192     Document Type: Review

References (38)

1. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL: The implications of regional variations in Medicare spending. Part 2: Health outcomes and satisfaction with care. Ann Intern Med 2003;138:288-298. (Pubitemid 36205925)
2. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.
3. Fox E, Landrum-McNiff K, Zhong Z, Dawson NV, Wu AW, Lynn J: Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA 1999;282:1638-1645. (Pubitemid 29513970)
4. Salpeter SR, Luo EJ, Malter DS, Stuart B: Systematic review of non-cancer presentations with a median survival of 6 months or less. Am J Med (in press) doi:10.1016/j.amjmed .2011.07.028.
5. SEER Survival Monograph: Cancer survival among adults: U.S. SEER Program, 1988-2001. Patient and tumor charac-teristics. Bethesda, MD: NIH Pub. No 07-6215; 2007.
6. Glare P, Christakis NA: Prognosis in Advanced Cancer. New York: Oxford University Press, 2008.
7. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
8. Wachtel T, Allen-Masterson S, Reuben D, Goldberg R, Mor V: The end stage cancer patient: Terminal common pathway. Hosp J 1988;4:43-80. (Pubitemid 19064462)
9. Gospodarowicz MK, O'Sullivan B, Sobin LH, International Union against Cancer: Prognostic Factors in Cancer, 3rd ed. Hoboken: Wiley-Liss, 2006.
10. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980;45:2220-2224. (Pubitemid 10150440)
11. Allard P, Dionne A, Potvin D: Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care 1995;11:20-24.
12. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193. (Pubitemid 14138407)
13. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-2007. (Pubitemid 14127662)
14. Oken MM, Creech RH, Tormey DC, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655. (Pubitemid 13149996)
15. Chow E: Recursive partitioning analysis of prognostic fac-tors for survival in patients with advanced cancer. Int J Radiat Oncol Biol Phys 2009;73:1169-1176.
16. Cancers and other neoplasms. 2010. http://clinicaltrials .gov/ct2/search/browse?brwse=cond-cat-BC04 (Last accessed October 21, 2010).
17. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemo-therapy in advanced breast cancer. Eur J Cancer 2000;36: 1498-506. (Pubitemid 30619002)
18. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V: Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 2000;83:431-437. (Pubitemid 30487852)
19. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C: Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
20. Pignon JP, le Maitre A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radio-ther Oncol 2009;92:4-14.
21. Kantarjian H, O'Brien S, Cortes J, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 2006;106:1090-1098.
22. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Will-man CL, Godwin JE, Anderson JE, Petersdorf SH: Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
23. Billingham LJ, Cullen MH: The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001;12:1671-1675. (Pubitemid 34105655)
24. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Mu-derspach L, Roman L, Morrow CP, Burnett A, Muggia FM: Treatment of patients with ovarian carcinoma with pegy-lated liposomal doxorubicin: Analysis of toxicities and pre-dictors of outcome. Cancer 2001;91:90-100. (Pubitemid 32052618)
25. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD: Prognostic factors for response to cisplatin-based chemo-therapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2010;116:44-49.
26. Dumontet C, Mounier N, Munck JN, Bosly A, Morschauser F, Simon D, Marit G, Casasnovas O, Reman O, Molina T, Reyes F, Coiffier B: Factors predictive of early death in pa-tients receiving high-dose CHOP (ACVB regimen) for ag-gressive non-Hodgkin's lymphoma: A GELA study. Br J Haematol 2002;118:210-217. (Pubitemid 34779539)
27. Patil CG, Pricola K, Garg SK, Bryant A, Black KL: Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev 2010:CD006121.
28. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP: Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-6109. (Pubitemid 43085049)
29. Haubt BJ:Characteristics of hospice care discharges and their length of service: United States, 2000. Vital Health Stat 2003;13.
30. Christakis NA, Lamont EB: Extent and determinants of error in doctors' prognoses in terminally ill patients: Pospective cohort study. BMJ 2000;320:469-472. (Pubitemid 30173113)
31. NHPCO Facts and Figures: Hospice Care in America. 2010. www.nhpco.org/files/public/Statistics-Research/Hospice- Facts-Figures-Oct-2010. pdf (Last accessed October 21, 2010).
32. Christakis NA, Iwashyna TJ: Attitude and self-reported practice regarding prognostication in a national sample of internists. Arch Intern Med 1998;158:2389-2895.
33. Gordon EJ, Daugherty CK: "Hitting you over the head": Oncologists' disclosure of prognosis to advanced cancer patients. Bioethics 2003;17:142-168. (Pubitemid 36416572)
34. Hagerty RG, Butow PN, Ellis PM, Lobb EA, Pendlebury SC, Leighl N, MacLeod C, Tattersall MH: Communicating with realism and hope: Incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 2005;23:1278-88. (Pubitemid 46202286)
35. Mack JW, Wolfe J, Cook EF, Grier HE, Cleary PD, Weeks JC Hope and prognostic disclosure. J Clin Oncol 2007;25:5636-5642.
36. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, Lynn J, Phillips RS: Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-1714. (Pubitemid 28247301)
37. Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K: Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246. (Pubitemid 46349540)
38. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ: Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.